Our results also show that SHP2 may be a potential therapeutic target to improve the sensitivity of GC cells to cisplatin, which provides a theoretical basis for SHP099 combined with cisplatin in the treatment of GC. The gene discussed is PTPN11; the disease is gastric cancer.